The U.S. Food and Drug Administration (FDA) is now slated to decide by next year whether or not to approve the novel injection therapy obexelimab for immunoglobulin G4-related disease (IgG4-RD). The regulatory agency has accepted a biologics license application (BLA) from Zenas Biopharma, the therapy’s developer,…
Discussion
Before I was diagnosed with IgG4-related disease (IgG4-RD) in 2015, information about the symptoms was virtually nonexistent. I remember searching online for “intermittent chronic eyelid swelling” and finding very little. At one point, I came across only a handful of TikTok videos, and even those weren’t very helpful or…
Discussion
IgG4‑related disease (IgG4-RD) doesn’t behave like an illness; it behaves like a character — one with a personality so distinct that, after a while, I stopped describing symptoms and started describing traits. If diseases had temperaments, IgG4‑RD would be the quiet, calculating type. The one that sits in the…
Get regular updates to your inbox.
